Inclusion Criteria:

          1. Histologically or cytologically confirmed stage IV, non-squamous, wild-type
             EGFR,ALK-negative NSCLC

          2. Signed ICF and ability to comply with this protocol

          3. 18 years of age or older

          4. ECOG performance status of 0-1

          5. Patients must have measurable disease as defined by RECIST v. 1.1

          6. Systematic treatment naive with respect to the currently diagnosed NSCLC

          7. Patients must have recovered from toxicity of previous therapy. Recovery is defined as
             less than or equal to grade 2 toxicity according to National Cancer Institute Common
             Terminology Criteria for Adverse Events (NCI CTCAE) (except alopecia).

          8. Sufficient hematologic and organ function for leukapheresis and chemotherapy:

               -  WBC equal to or higher than 4×10^9 /L

               -  Neutrophil equal to or higher than 1.5×10^9 /L

               -  PLT equal to or higher than 100×10^9 /L

               -  Hemoglobin equal to or higher than9 g/dL (90 g/L)

               -  Total bilirubin less than or equal to 1.5 times upper limit of normal (benign
                  hereditary hyperbilirubinemias, eg, Gilbert's syndrome are permitted)

               -  Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and
                  alkaline phosphatase (ALP) should be less than or equal to 3 times upper limit of
                  normal. ALP, AST, and ALT less than or equal to 5 times upper limit of normal is
                  acceptable if liver has tumor involvement.

               -  Creatinine clearance equal to or higher than 45 mL/min (calculated with the
                  standard Cockcroft and Gault formula)

          9. Women of childbearing potential and sexually active males must agree to use an
             accepted and effective method of contraception (hormonal or barrier methods,
             abstinence) prior to study entry and for the duration of the treatment plus 3 months

        Exclusion Criteria:

          1. Known active/untreated CNS metastases

          2. Any known primary immunodeficiency

          3. Any preexisting medical condition requiring long term chronic steroid or
             immunosuppressive therapy

          4. HIV positivity, hepatitis B and/or C infection, syphilis

          5. Past or current history of malignant neoplasm other than lung carcinoma, except for
             adequately treated non-melanoma skin cancer, in situ carcinoma of the cervix, or other
             cancer curatively treated and with no evidence of disease for at least five years

          6. Patient's significant co-morbidities:

               -  Cardiovascular diseases - unstable angina pectoris, uncontrolled hypertension,
                  myocardial infarction or ventricular arrhythmia or stroke within a 6-month period
                  before randomization, congestive heart failure or cardiac arrhythmia not
                  controlled by treatment

               -  Active severe infections or other severe medical condition

          7. Participation in a clinical study using experimental therapy and
             immunotherapy,monoclonal antibodies within the last 4 weeks prior to study entry

          8. Pregnant or breastfeeding woman

          9. History of severe hypersensitivity to pemetrexed and carboplatin and their
             ingredients, and to DCVAC ingredients